Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Case, James Brett

Class:IdPerson:9680279
_displayNameCase, James Brett
_timestamp2020-03-26 16:48:07
created[InstanceEdit:9680260] Jassal, Bijay, 2020-03-26
firstnameJames Brett
initialJB
surnameCase
(author)[LiteratureReference:9680275] Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
[LiteratureReference:9707796] De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
[LiteratureReference:9979268] The IFIT2-IFIT3 antiviral complex targets short 5' untranslated regions on viral mRNAs for translation inhibition
[Change default viewing format]
No pathways have been reviewed or authored by Case, James Brett (9680279)